VaxNewMo gets highlighted for vaccine breakthrough

VaxNewMo, a St. Louis bioscience startup, is working to develop broader, more affordable vaccines at a faster rate with its patented technology.

 

“VaxNewMo is developing more affordable pneumococcal conjugate vaccines that provide broader protection against more strains of bacteria that cause pneumococcal pneumonia,” Dr. Mario Feldman, co-founder of VaxNewMo and associate professor of molecular microbiology at Washington University School of Medicine St. Louis, said.

 

No Comments

Post A Comment